« Return to News | CROs/Service Providers

MDS Warns Shareholders Not to Expect Much from Early-Stage Sale

Thursday, January 28, 2010 08:07 AM

As MDS continues its efforts to sell the rest of its contract research division, the company is preparing investors for less-than-expected earnings from that sale.

MDS, which sold its late-stage operations last year and still seeks a buyer for its early-stage business, plans to focus on MDS Nordion, the company’s medical imaging business. In its annual report published this week, MDS told investors that the sale of the early-stage business will likely garner lower sale proceeds than previously expected, due to “continued deterioration of market conditions, the declining early stage customer base and new developments in the ongoing strategic review process.”  

The company said that some MDS customers have expressed concern  over the company’s restructuring and decreased focus on early stage, resulting in a reduction of orders and revenues. As a result, the sale proceeds—when and if the early-stage business sells—may not be enough to fund a distribution to shareholders.

The early-stage business was listed under discontinued operations in the annual report.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.